Cellectis (CLLS)

Oncology Corporate Profile

Stock Performance

15.9100
-0.4500

HQ Location

430 East 29th Street
New York, NY 10016

Company Description

Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. Cellectis has 17 years of expertise in gene editing based on its flagship TALENĀ® technology and pioneering electroporation system PulseAgile. This enables us to develop a new generation of immunotherapy product candidates with additional safety and efficacy attributes and equip them to resist mechanisms that inhibit immune system activity.

Website: https://www.cellectis.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
UCART123CAR T-cell therapyAcute Myelogenous Leukemia (AML)I
UCART123CAR T-cell therapyBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)I

Source: https://www.cellectis.com/

Recent News Headlines

There are no news items to display